London, United Kingdom
Viabio SIA is a biotechnology startup based in the United Kingdom, founded in 2023. The company's slogan "Innovative technologies for high-quality 3D bioprinting optimization and viability control using AI" underscores its focus on developing cutting-edge solutions for 3D bioprinting. Viabio is dedicated to 3D bioprinting software development aimed at enhancing the viability of bioprinted tissues and organs through the utilization of AI and mathematical modeling.
Viabio's scientific team has been at the forefront of R&D, working on pioneering state-of-the-art technologies to improve the results of human tissues and organs 3D bioprinting. The company's primary objective is to improve the efficiency and scalability of 3D bioprinting technologies using innovative AI-driven methodologies.
As of now, there is no public information available about Viabio's recent investment and the involved investors. Nevertheless, Viabio's focus on leveraging advanced technologies for bioprinting optimization positions the company as a prospective player in the rapidly evolving field of biotechnology.
